Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.55 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.38 |
| ▸ | CDK2 | P24941 | 6/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | CTSV | O60911 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3026003 | 0.86 | CCNE1 (0.48) | MAPKAPK2CDK1CCNE1CDK2PDGFRA | |
| SCHEMBL3025994 | 0.86 | CCNE1 (0.48) | MAPKAPK2CDK1CCNE1CDK2PDGFRA | |
| SCHEMBL3011874 | 0.79 | MAPKAPK2 (0.45) | MAPKAPK2SIRT2CTSVCTSLF10 | |
| SCHEMBL3006282 | 0.79 | CDK2 (0.45) | MAPKAPK2CDK1CCNE1CDK2PDGFRA | |
| SCHEMBL3006286 | 0.79 | CDK2 (0.45) | MAPKAPK2CDK1CCNE1CDK2PDGFRA | |
| SCHEMBL3006441 | 0.79 | CDK2 (0.42) | MAPKAPK2CDK1CCNE1CDK2PDGFRA | |
| SCHEMBL3006444 | 0.79 | CDK2 (0.42) | MAPKAPK2CDK1CCNE1CDK2PDGFRA | |
| SCHEMBL3009064 | 0.78 | CDK1 (0.51) | MAPKAPK2CDK1CCNE1CDK2PDGFRA | |
| SCHEMBL3021799 | 0.77 | FLT3 (0.40) | CCNE1CDK2PDGFRAFLT3BTK | |
| SCHEMBL3021801 | 0.77 | FLT3 (0.40) | CCNE1CDK2PDGFRAFLT3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723336-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP3K3, MAP3K2, MAP4K3 | MAPKAPK2 24/4885CDK1 105/4885CCNE1 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.